SUNDAY, MARCH 21
Arrival and Registration

MONDAY, MARCH 22
Welcome and Keynote Session (Joint)
Helen H. Hobbs, University of Texas Southwestern Medical Center, USA
PNPLA3's Role in NAFLD
Hashem B. El-Serag, Baylor College of Medicine, USA
Changing Epidemiological Trends in Non-Alcoholic Fatty Liver Disease versus Viral-Associated Hepatobiliary Cancers
Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fibrogenesis in the Pathogenesis of Hepatobiliary Cancers (Joint)
Lopa Mishra, George Washington University, USA
TGF-beta Signaling in Liver Fibrosis and Hepatocellular Carcinoma
Speaker to be Announced
Short Talks Chosen from Abstracts

TUESDAY, MARCH 23
Tumor Microenvironment and Hepatobiliary Cancers (X6)
Silvia Afio, Columbia University, USA
The Role of Cancer-Associated Fibroblasts in the Pathogenesis of Hepatobiliary Cancers
Amaia Lujambio, Icahn School of Medicine at Mount Sinai, USA
Mechanisms of Immune Escape in Intrahepatic Cholangiocarcinoma: Molecular Drivers and Prognostic Implications
Gregory J. Gores, Mayo Clinic, USA
Targeting the Tumor Microenvironment for Cholangiocarcinoma Therapy
Short Talks Chosen from Abstracts

Role of Lipids in NAFLD (X5)
Mitchell A. Lazar, Perelman School of Medicine, University of Pennsylvania, USA
Circadian Contributions to NAFLD
Daniel A. Heller, Memorial Sloan Kettering Cancer Center, USA
Lipid Dysregulation in Inflammation, NASH, and Cancer
Catherine Postic, INSERM, Institut Cochin, France
Altered Insulin Signaling and Glucose Toxicity in NAFLD
Tobias C. Walther, Harvard School of Public Health, USA
Lipid Droplet Biology in NAFLD
Short Talks Chosen from Abstracts

Hepatobiliary Cancer Biomarkers (X6)
Yujin Hoshida, UT Southwestern Medical Center, USA
Liver Cancer Risk-Predictive Molecular Biomarkers Specific to Clinico-Epidemiological Contexts
Irene Oi Lin Ng, University of Hong Kong, Hong Kong
Molecular Biomarkers in Hepatocellular Carcinoma
Augusto Villanueva Rodriguez, Icahn School of Medicine at Mount Sinai, USA
Liquid Biopsy in Hepatobiliary Cancers
Short Talks Chosen from Abstracts

NAFLD and CVD (X5)
Speaker to be Announced
Jay D. Horton, University of Texas Southwestern Medical Center, USA
Molecular Mediators of NAFLD and Hyperlipidemia
Henry N. Ginsberg, Columbia University College of Physicians and Surgeons, USA
Loss of Function of TorsinA, an ER Localized AAA ATPase Causes Severe Steatosis with Decreased VLDL Secretion and Abnormal ER Lipid Droplets
Short Talks Chosen from Abstracts

**Poster Session 2**

**WEDNESDAY, MARCH 24**

**Genomic and Epigenomic Heterogeneity in Hepatobiliary Cancers (X6)**

**Xin Wei Wang**, NCI, National Institutes of Health, USA
Causes and Functional Intricacies of Intertumor and Intratumor Heterogeneity in Primary Hepatobiliary Cancers

**Jessica Zucman-Rossi**, University Paris Descartes-HEGP, France
Molecular Subtypes of Hepatocellular Carcinoma are Related to Specific Tumor Phenotypes

**Renumathy Dhanasekaran**, Stanford University, USA
Complexities of Genetic Heterogeneity in Hepatocellular Carcinoma

**Bin Tean Teh**, Duke-NUS Medical School, Singapore
Cholangiocarcinoma in Diverse Populations

**Short Talks Chosen from Abstracts**

**Pathways to NASH (X5)**

Speaker to be Announced

**Mark A. McNiven**, Mayo Clinic, USA
Lipid Droplet Formation and Lipophagy in Fatty Liver Disease

**Eran Elinav**, Weizmann Institute of Science, Israel
Lipid-Associated Macrophages Control Metabolic Homeostasis

**Short Talks Chosen from Abstracts**

**Emerging Therapies for NASH-I (X5)**

**Morris J. Birnbaum**, Pfizer Inc., USA
DGAT2 Inhibition for NASH

**Greg Steinberg**, McMaster University, Canada
Cellular Energy Sensors and Metabolism

**Short Talks Chosen from Abstracts**

"Omics" for Precision Medicine of Hepatobiliary Cancers (X6)

**Josep Llovet**, Icahn School of Medicine at Mount Sinai, USA
Integrative "Omics" and Precision Medicine for Hepatocellular Carcinoma

**Jesper Bøje Andersen**, University of Copenhagen, Denmark
Defining Distinct Subtypes of Intrahepatic Cholangiocarcinoma by Molecular Profiling: Diagnostic, Prognostic, and Therapeutic Applications

**Robert F. Schwabe**, Columbia University, USA
Discovery of Subgroup-Specific HCC Master Regulators by Systems Biology Approaches

**Short Talks Chosen from Abstracts**

**Advances in Molecular and Immune Targeting of Hepatobiliary Cancers (X6)**

**Bruno Sangro**, Clinica Universidad de Navarra, Spain
Targeted Agent and Immune-Based Therapies for Hepatocellular Carcinoma

**Tim F. Greten**, NCI, National Institutes of Health, USA
Immunotherapies for Hepatobiliary Cancers: Current Status and Future Perspectives

**R. Kate Kelley**, University of California, San Francisco, USA
Developing Clinical Trials of Novel Therapeutic Agents and Treatment Combinations for Intrahepatic Cholangiocarcinoma

**Short Talks Chosen from Abstracts**

**Emerging Therapies for NASH-II (X5)**

**Kendra K. Bence**, Pfizer Inc., USA
Inhibition of Fructose Metabolism for the Treatment of NAFLD

**Chuhan Chung**, Gilead Sciences, USA
ACC Inhibitors for NASH

**Lei Ling**, NGM Biopharmaceuticals, USA
Therapeutic FGF19 in Non-Alcoholic Steatohepatitis

**Short Talks Chosen from Abstracts**

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X6)

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X5)

**THURSDAY, MARCH 25**

Departure